Perkin elmer radionuclides/radioisotopes (BLU002Z001MC) adenosine 5'-triphosphate [gamma-32-P]
Ended Awarded Last action
- Contract number
- HHSN26100034
- Awardee
-
Revvity Health Sciences, Inc. UEI G2TETZJTELL4 Part of Revvity Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,907
Award facts
- Contract value 100% obligated
- $7,907.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Shelton, CT 06484, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$718 | |
| Original award | $8,625 |
About this award
The National Cancer Institute awarded a BPA call contract valued at $7,907 to Revvity Health Sciences, Inc. (doing business as PerkinElmer Inc.) on November 5, 2013, with an ultimate completion date of November 6, 2014. The contract calls for the procurement of Perkin Elmer radionuclides/radioisotopes, specifically Adenosine 5'-Triphosphate [Gamma-32-P], to be performed at the contractor's facility in Shelton, Connecticut. This award utilizes a firm fixed-price pricing structure under an existing blanket purchase agreement and carries no small business set-aside designation, reflecting the specialized and technical nature of the radioisotope supply requirement.
Revvity Health Sciences operates as a subsidiary of parent company Revvity Inc. and serves as an established supplier of advanced scientific and medical technologies to federal agencies. The company's procurement of radioisotopes for the National Cancer Institute aligns with NCI's research support mission, as radiolabeled compounds such as Gamma-32-P are essential tools for biochemical research, cellular studies, and diagnostic applications. Revvity maintains a significant federal contract portfolio that includes multiple indefinite delivery vehicles, including a $10 million blanket purchase agreement with the National Eye Institute that covers laboratory supplies, medical and scientific equipment, and radionuclides/radioisotopes through December 2025, providing additional context for the company's role as a key federal supplier of specialized research materials.
Quick answers
Who was awarded contract HHSN26100034?
HHSN26100034 was awarded to Revvity Health Sciences, Inc. by National Cancer Institute (National Institutes of Health) on November 5, 2013.
How much is contract HHSN26100034 worth?
The government has obligated $7,907 on HHSN26100034.
Is contract HHSN26100034 an order under another contract?
Yes. HHSN26100034 is a BPA call under HHSN263199800049720B, a blanket purchase agreement.
Was contract HHSN26100034 competed?
The extent of competition for HHSN26100034 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award